Agios Pharmaceuticals (AGIO) Q1 EPS of ($1.45) was $0.19 better than consensus estimates, with revenue up 46% YoY to $8.19M.
Agios Pharmaceuticals (AGIO) posted Q1 EPS of ($1.45), beating consensus estimates of ($1.64) by $0.19. Revenue increased 46% YoY to $8.19M. Despite the positive earnings surprise, AGIO's stock price declined by $0.04, reaching $34.54. The company has a market cap of $1.96B, a P/E ratio of -5.44, and a beta of 0.81. Analyst ratings for AGIO are mixed, with an average rating of "Hold" and a consensus price target of $34.75.
May 03, 2024
5 Articles